Back to Schemes

Pharmacogenetics (DPYD / UGT1A1 only)

Product Code: 05-PHARM-DPYD-26

From £475.00 Early Bird

Early Bird Deadline: 31/01/2026

Deadline to order: 28/02/2026

DPYD and/or UGT1A1 pharmacogenetic testing for drug response and efficacy (Germline DNA).

Target/Genes:

Clinically relevant variants in the DPYD and/or UGT1A1 genes ONLY. It is NOT mandatory to test both genes.If you undertake panel testing for additional pharmacogentic markers, then you are advised to participate in our Pharmacogenetics panel based EQA scheme.

Technology:

CNV, MLPA, NGS, Panel testing, PCR based, Sanger sequencing

Language:

English, German

Sample Type:

DNA (in TE Buffer)

Accredited:

Pending

Sample Dispatch Date:

June 2026

Survey Period:

June - August 2026

Final Results:

December 2026 - January 2027

You can complete purchase on our secure partner site.

EQA Assessment

The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy. 

To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment.

More information, including the EMQN validation panel, is available on request and complete details will be provided in the scheme instructions. 

Sample Details

Three mock clinical cases with matching samples will be provided. Approximately 2µg DNA per sample is provided. Complete information will be available in the scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

How it works

Register

  • Enrol before the closing date
  • EMQN ships EQA samples or digital cases

Test & submit results

  • Analyse samples in your routine workflow
  • Upload results via your website account

Review & get certified

  • EMQN assesses your data
  • Receive your individual results, EQA summary report & certificate of participation

Enquire about this scheme

Contact Information

added wishlist!
View Wishlist

0

View Wishlist

Register Interest

Express your interest in ''.